Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy hope for babies with fatal muscle disease

NCT ID NCT06191354

First seen Nov 21, 2025 · Last updated Jun 02, 2026 · Updated 23 times

Summary

This study tests a new gene therapy called SKG0201 in 12 infants with spinal muscular atrophy type 1, a severe muscle-weakening disease. The treatment aims to improve survival and motor skills by delivering a working gene. Researchers are checking safety and how well the therapy works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Children's Medical Center, Children's Hospital of Fudan University

    Shanghai, China

  • West China Sencond Hospital, Sichuan University / West China women's and children's Hospital

    Chengdu, Sichuan, China

  • Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

    Shanghai, 200092, China

Conditions

The condition(s) this trial relates to.

Spinal Muscular Atrophies of Childhood spinal muscular atrophy, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.